NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 to 17 ID5104

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company • Novartis (dabrafenib, trametinib) Patient/carer groups • Astro Brain Tumour Fund • Black Health Agency for Equality • Brain and Spine Foundation • Brain Tumour Action • Brainstrust • Cancer 52 • Cancer Black Care • Cancer Equality • Childhood Cancer Patients Alliance • Children with Cancer • Headcase Cancer Trust • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Neurological Alliance • South Asian Health Foundation • Solving Kids Cancer • Specialised Healthcare Alliance • Teenage Cancer Trust • Tenovus Cancer Care • The Brain Charity • The Brain Tumour Charity • Young Lives vs Cancer Healthcare professional groups • Association of British Neurologists • Association of Cancer Physicians • Association of Surgeons of Great Britain and Ireland • British Association of Surgical Oncology	General • All Wales Therapeutics & Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee Possible comparator companies • None Relevant research groups • Andrew McCartney Trust Fund for Brain Tumour Research • Brain Tumour Research • Brain Tumour Research Campaign • Cochrane Childhood Cancer Group • Cochrane UK • Genomics England • Institute of Cancer Research • Institute of Neurology, UCL • MRC Clinical Trials Unit • National Cancer Research Institute • National Institute for Health Research

Appendix C

Consultees	Commentators (no right to submit or appeal)
• British Geriatrics Society • British Institute of Radiology • British Oncology Pharmacy Association • British Psychosocial Oncology Society • British Skull Base Society • Cancer Research UK • Children's Cancer & Leukaemia Group • National Neuroscience Advisory Group • Neonatal and Paediatric Pharmacists Group • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • Society of British Neurological Surgeons • UK Clinical Pharmacy Association • UK Oncology Nursing Society <u>Others</u> • Department of Health and Social Care • NHS England	• Oracle Cancer Trust <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

[1] Non-company consultees are invited to submit statements relevant to the group they are representing.

